Introduction {#sec1}
============

Psoriasis is an inflammatory, proliferative and chronic skin disease with an incidence of 2--3% worldwide and is characterized by remission and recurrences. It is clinically characterized by silvery-white crust-coated erythematous plaques \[[@cit0001]\]. The disease is considered to have a genetic tendency and caused by triggering factors like trauma, infection, drug and stress. Pathogenesis of the disease is still not clearly explained although an ample amount of studies have been conducted for a long time \[[@cit0002]\]. The common idea is that inflammation triggered by oxidative stress plays a role in etiopathogenesis \[[@cit0003], [@cit0004]\]. On the other hand, another hypothesis proposes that psoriasis arises from reactive oxygen species (ROS) production due to over-expression of pro-inflammatory cytokines \[[@cit0005], [@cit0006]\].

C-reactive protein (CRP) is an acute phase protein released from the liver in response to interleukin-6 (IL-6) and a sensitive inflammation marker \[[@cit0007]\]. CRP was reported to be able to be used as an inflammation marker in many conditions like psoriasis, rheumatoid arthritis, atopic dermatitis, cancer and cardio-vascular diseases \[[@cit0007], [@cit0008]\].

While free radicals have useful functions like protection from infections, killing of cancer cells and detoxification of xenobiotics when in normal ranges, they tend to show harmful effects through structural changes on lipids, proteins and nucleic acids when their levels are high \[[@cit0009], [@cit0010]\]. Oxidative stress is a process which triggers inflammation. It was reported to play a role in etiopathogenesis of many skin diseases including psoriasis. Myeloperoxidase (MPO) shows microbicidal effects by forming ROS during degranulation of activated polymorphonuclear leukocytes (PMNL). However, when excessive ROS occurs in this way, it can cause tissue damage, lipid peroxidation and increased systemic oxidative stress \[[@cit0011]\]. Cutaneous accumulation of neutrophils was shown in psoriasis patients in many studies \[[@cit0012]\]. Therefore, the MPO level may be helpful in etiopathogenesis of psoriasis as it is the biomarker of neutrophil/monocyte activation \[[@cit0012], [@cit0013]\].

Metalloproteins may be helpful in investigating the aetiology as they play a role in oxidant--antioxidant mechanisms. The increase in oxidants triggers the activation of anti-oxidant defence mechanisms. Enzymatic antioxidant defence mainly includes glutathione peroxidase (GP), superoxide dismutase (SOD) and, catalase (CAT) \[[@cit0004]\]. However, MPO and CAT compete for H~2~O~2~ use. In addition, many inflammatory respiratory tract diseases were reported to be related with abnormal MPO/CAT ratios \[[@cit0014]\]. CP also shows anti-oxidant-like ferroxidase activity (FOX), it plays an important role as free oxygen radical scavenger \[[@cit0015]\]. The ceruloplasmin level may be an indicator related with the inflammatory process. Despite many studies investigating trace element levels in psoriasis, a limited number of studies have focused on the role of metal-binding proteins in psoriasis.

Trace elements are essential for biochemical processes in the body and play a role in immunologic and inflammatory reactions. However, keratinization and melanin formation are enzyme-dependent processes and may be affected by deficiencies or excesses of trace elements \[[@cit0016]\]. While SOD contains copper (Cu) and zinc (Zn) as a cofactor, GP contains selenium (Se) \[[@cit0017]\]. So Cu, Zn and Se contribute to elimination of free radicals through antioxidant enzyme systems \[[@cit0012]\]. However the studies on the role of trace elements and anti-oxidant enzymes in etiopathogenesis of psoriasis have revealed conflicting results. Levels of Cu, Zn, Se, SOD, GP and CAT were found to be high in some studies, low in some and unchanged in others \[[@cit0005], [@cit0018]--[@cit0024]\].

Aim {#sec2}
===

The aim of this study is to contribute a little bit to the elucidation of the etiopathogenesis of psoriasis with a relatively large number of patients and a broad range of biomarkers. Therefore, we evaluated the levels of CRP (as a biomarker of inflammation), ischemia-modified albumin (IMA), FOX, MPO, CAT (as indicators of oxidative stress) and trace elements (Cu, Zn, Se, Fe, Mg, Na, K, Ca, P) in psoriasis patients.

Material and methods {#sec3}
====================

A total of 147 participants including 87 psoriasis patients and 60 healthy individuals who were matched for age and gender and did not have any systemic or skin diseases and were admitted to the dermatology clinic of the hospital between November 2017 and April 2018 were included in the study. The study was approved by the local ethics committee. Written informed consent form was obtained from all participants prior to the study. Diagnosis of psoriasis was made based on clinical findings and/or histopathology reports. The psoriasis patients who were under treatment (who had received any systemic or local therapy within the last month), pregnant or lactating women and the patients who had diabetes mellitus, hypertension, psychiatric disorders, cardiac problems and skin diseases other than psoriasis were excluded from the study.

Disease severity was determined based on the involved body area. According to this, involvement of \< 3%, 3--10% and \> 10% of the body was classified as mild, moderate and severe disease, respectively.

Venous blood samples were obtained from the antecubital vein of the participants, centrifuged at 3500 rpm for 5 min after being stored at room temperature for 30 min and sera were transferred into Eppendorf tubes and stored at --80°C until the day of analyses.

Levels of Na and K were measured with the ion selective electrode method; Ca, P, Mg, Fe and CRP levels were measured spectrophotometrically with auto-analyser (Architect c8000, Abbott, Illinois, USA) and with the same brand of device using kits.

Serum Se, Cu, Zn levels were measured with the atomic absorption spectrometer (Thermo ICE 3000, Tokyo, Japan). Serum Cu and Zn levels were measured with deuterium background correction by using the flame atomic absorption spectrometer; the selenium level was measured with Zeeman background correction by using the electro-thermal atomic absorption spectrometer. Standard Cu, Zn and Se solutions were prepared by dilution of certified standard solutions (high purity standards, Charleston, SC, USA). Two level quality control material (Seronorm, Billingstad; Norway) was used. Samples were diluted with 1% (1.10) nitric oxide (HNO~3~). Standards were measured in the ranges of 0.05--1 ppm, 0.1--0.5 ppm and 2.5--25 ppb for Cu, Zn and Se, respectively.

An ischemia-modified albumin (IMA) level was analysed by using an albumin cobalt binding test. 50 µl of 0.1% cobalt (II) chloride (CoCl~2~, 6H~2~O) (Sigma, Aldrich, Germany) was added to patient serum and incubated for 10 min for albumin's binding cobalt following the mixing procedure. Afterwards, 50 µl of 1.5 mg/ml ditiotreitol was added and incubated for 2 min after the mixing procedure and 1 ml of 0.9% NaCl solution was added for reducing binding capacity. Blind solution was prepared with the same method but by using distilled water instead of ditiotreitol. Absorbance of the samples was measured spectrophotometrically (Varioskan LUX Multimode Microplate Reader) at 470 nm. Results were expressed as mg/dl.

Catalase (CAT) activity was measured by using the method described by Goth \[[@cit0025]\]. According to this method, 0.2 ml of the sample is added into 1 ml substrate (65 µmol H~2~O~2~, 60 mmol/l sodium-potassium phosphate buffer pH 7.4) and incubated at 37°C for 60 min. Enzymatic reaction is stopped with 1 ml 32.4 mM ammonium molybdate. The yellow complex composed of molybdate and H~2~O~2~ is read against blank at 405 nm.

Serum MPO activity was measured by using the modified form of the method described by Bradley. This measurement is based on absorbance at 460 nm proportionally with the amount of yellowish-orange product formed with the oxidation of o-dianisidine with MPO in the presence of hydrogen peroxide \[[@cit0026]\].

Ferroxidase activity levels were measured with the method described by Erel \[[@cit0027]\]. This method is automatic and colorimetric and is based on the enzymatic oxidation of the iron ion to the ferric ion.

Statistical analysis {#sec3.1}
--------------------

Data were evaluated by using SPSS 21 (SPSS, Chicago, IL, USA) software program. The association between two groups with regard to gender was evaluated with c^2^ test. Normality distribution of continuous variables was evaluated with Kolmogorov-Smirnov test. For comparison of mean values between two groups, normally distributed data were evaluated with independent sample *t* (Student's *t*) test and the non-normally distributed data were evaluated with Mann-Whitney *U* test. For detection of the correlation between the continuous variables, Pearson test was used for normally distributed data and Spearman correlation analysis was used for the data not normally distributed. ANOVA test was used to evaluate the differences between the means of continuous variables in the severity groups. Kruskal Wallis test was used to evaluate the differences between the means of non-parametric continuous variables in the severity groups. A *p*-value of \< 0.05 was accepted as statistically significant.

Results {#sec4}
=======

A total of 147 participants (87 patients and 60 healthy individuals) were included in the study. The parameters showed a normal distribution except the disease duration (DD), body mass index (BMI) and CRP. Patient and control groups were similar with regard to gender, age and BMI ([Table 1](#t0001){ref-type="table"}).

###### 

Comparison of demographic characteristics between patient and control groups

  Parameter                                            Patient group          Control group          *P*-value
  ---------------------------------------------------- ---------------------- ---------------------- -----------
  Gender (M/F)^χ2^                                     47/40                  26/34                  0.255
  Age \[year\][^₸^](#tf1-1){ref-type="table-fn"}       32.75 ±15.64           30.80 ±12.89           0.428
  DD \[year\]                                          7 (0--37)                                     
  BMI \[kg/m^2^\][^\#^](#tf1-2){ref-type="table-fn"}   24.22 (12.76--44.92)   23.23 (16.90--34.37)   0.692

Student t test

Mann-Whitney U test

χ2 -- chi square test. Median (minimum--maximum), mean ± SD, DD -- disease duration, BMI -- body mass index.

While an increase was detected in CRP, IMA, IMA/Alb, Cu, CAT and FOX levels in the patient group as compared to the control group; Alb, Se and Zn levels were found to decrease and Na, K, Ca, P, Fe, Mg and MPO levels were found not to change ([Table 2](#t0002){ref-type="table"}).

###### 

Comparison of mean values of continuous variables between patient and control groups[^₸^](#tf2-1){ref-type="table-fn"}

  Parameter                                          Patient group       Control group       *P*-value
  -------------------------------------------------- ------------------- ------------------- -------------------------------------------
  CRP \[mg/dl\][^\#^](#tf2-2){ref-type="table-fn"}   0.02 (0.02--5.99)   0.02 (0.02--1.85)   0.04[\*](#tf2-3){ref-type="table-fn"}
  Se \[μg/l\]                                        76.68 ±22.86        89.04 ±31.17        0.006[\*](#tf2-3){ref-type="table-fn"}
  Zn \[μg/dl\]                                       111.88 ±38.33       131.41 ±39.72       0.003[\*](#tf2-3){ref-type="table-fn"}
  Cu \[μg/dl\]                                       118.73 ±41.67       84.56 ±23.59        \< 0.001[\*](#tf2-3){ref-type="table-fn"}
  Na \[mEq/l\]                                       138.94 ±2.40        138.41 ±2.15        0.177
  K \[mEq/l\]                                        4.36 ±0.38          4.36 ±0.29          0.957
  Ca \[mg/dl\]                                       9.45 ±0.44          9.49 ±0.42          0.545
  P \[mg/dl\]                                        3.91 ±0.93          3.87 ±0.58          0.805
  Mg \[mg/dl\]                                       1.94 ±0.13          1.98 ±0.12          0.077
  Fe \[μg/dl\]                                       92.01 ±34.92        88.85 ±33.60        0.585
  IMA \[ΔABSU\]                                      0.23 ±0.06          0.18 ±0.05          \< 0.001[\*](#tf2-3){ref-type="table-fn"}
  Albumin \[g/dl\]                                   4.44 ±0.22          4.58 ±0.25          \< 0.001[\*](#tf2-3){ref-type="table-fn"}
  IMA/ALB \[AU\]                                     0.052 ±0.017        0.041 ±0.013        \< 0.001[\*](#tf2-3){ref-type="table-fn"}
  CAT \[kU/l\]                                       135.5 ±21.2         122.5 ±15.3         \< 0.001[\*](#tf2-3){ref-type="table-fn"}
  MPO \[U/l\]                                        107.82 ±33.51       98.96 ±34.73        0.123
  FOX \[U/l\]                                        503.79 ±85.64       425.06 ±108.08      \< 0.001[\*](#tf2-3){ref-type="table-fn"}

Student t test

Mann-Whitney U test

statistically significant difference.

Median (minimum--maximum), mean ± SD, ΔABSU -- absorbance unit, AU -- arbitrary unit, CRP -- C-reactive protein, Se -- selenium, Zn -- zinc, Cu -- copper, Na -- sodium, K -- potassium, Ca -- calcium, P -- phosphorus, Mg -- magnesium, Fe -- iron, IMA -- ischemia-modified albumin, IMA/ALB -- ischemia-modified albumin/albumin, CAT -- catalase, MPO -- myeloperoxidase, FOX -- ferroxidase.

When mean differences of continuous variables were analysed between disease severity groups, a significant difference was found only for FOX (ANOVA, *p* = 0.004) and disease duration (ANOVA, *p* = 0.009) ([Table 3](#t0003){ref-type="table"}). In addition, a difference was found between CRP median values (Kruskal Wallis, *p* = 0.045).

###### 

Mean differences of continuous variables between severity groups in psoriasis patients

  Parameter          Disease severity    ANOVA *p*                                                                                              
  ------------------ ------------------- ----------------------------------------------------- ------------------------------------------------ -----------------------------------------
  CRP \[mg/dl\]      0.02 (0.02--5.99)   0.7 (0.02--4.39)[^\#^](#tf3-4){ref-type="table-fn"}   0.02 (0.02--4.56)                                0.045[^Ќ^](#tf3-3){ref-type="table-fn"}
  Se \[μg/l\]        75.56 ±22.44        77.10 ±24.12                                          77.10 ±22.99                                     0.962
  Zn \[μg/dl\]       120.46 ±42.98       97.29 ±42.26                                          114.28 ±31.87                                    0.109
  Cu \[μg/dl\]       114.08 ±36.36       129.78 ±42.60                                         115.86 ±43.96                                    0.377
  IMA \[ΔABSU\]      0.228 ±0.0526       0.241 ±0.077                                          0.227 ±0.0707                                    0.713
  Albumin \[g/dl\]   4.47 ±0.21          4.45 ±0.21                                            4.415 ±0.2454                                    0.582
  IMA/ALB \[AU\]     0.0513 ±0.0131      0.0547 ±0.0185                                        0.0522 ±0.0184                                   0.789
  CAT \[kU/l\]       138.44 ±20.89       131.05 ±20.91                                         136.08 ±21.66                                    0.497
  MPO \[U/l\]        109.99 ±31.13       108.42 ±36.56                                         106.28 ±33.99                                    0.908
  FOX \[U/l\]        463.45 ±77.74       491.75 ±79.37                                         532.87 ±83.83[\*](#tf3-2){ref-type="table-fn"}   0.004
  DD                 5.71 ±5.87          7.24 ±8.37                                            11.83 ±9.03[^¥^](#tf3-1){ref-type="table-fn"}    0.009

Between mild and severe (p = 0.012).

Between mild and severe (p = 0.004).

Kruskal Wallis.

Between mild and moderate (p = 0.015).

ΔABSU -- absorbance unit, AU -- arbitrary unit, CRP -- C-reactive protein, Se -- selenium, Zn -- zinc, Cu -- copper, IMA -- ischemia-modified albumin, IMA/ALB -- ischemia-modified albumin/albumin, CAT -- catalase, MPO -- myeloperoxidase, FOX -- ferroxidase, DD -- disease duration.

The correlations between oxidative stress parameters, trace elements and CRP are presented in [Table 4](#t0004){ref-type="table"}.

###### 

Significant correlations between some parameters in psoriasis patients

  Parameter       *P*-value                                    *r*       Parameter       *P*-value                                    *r*
  --------------- -------------------------------------------- --------- --------------- -------------------------------------------- ---------
  Cu-IMA/ALB      \< 0.001[^ᴪ^](#tf4-1){ref-type="table-fn"}   0.503     CRP-Cu          \< 0.001[^Ω^](#tf4-2){ref-type="table-fn"}   0.589
  Cu-CAT          \< 0.001[^ᴪ^](#tf4-1){ref-type="table-fn"}   --0.714   CRP-(IMA/ALB)   \< 0.001[^Ω^](#tf4-2){ref-type="table-fn"}   0.704
  (IMA/ALB)-CAT   \< 0.001[^ᴪ^](#tf4-1){ref-type="table-fn"}   --0.489   CRP-CAT         \< 0.001[^Ω^](#tf4-2){ref-type="table-fn"}   --0.530
  IMA-ALB         \< 0.001                                     --0.601                                                                

Pearson correlation test

Spearman correlation analysis

Cu -- copper, IMA -- ischemia-modified albumin, ALB -- albumin, CAT -- catalase, CRP -- C-reactive protein.

A positive correlation was found between Cu and oxidative stress parameters CRP, IMA and IMA/ALB; and a negative correlation was found between Cu and albumin and CAT ([Table 5](#t0005){ref-type="table"}). A positive correlation was found between Zn and oxidative stress parameters; and a negative correlation was found with CAT ([Table 5](#t0005){ref-type="table"}).

###### 

Correlation analyses between trace elements and other parameters[^ᴪ^](#tf5-3){ref-type="table-fn"}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                         Se \[μg/l\]   Zn \[μg/dl\]                             Cu \[μg/dl\]                               
  ------------------------------------------------- ------------- ---------------------------------------- ------------------------------------------ --------------------------------------------
  CRP \[mg/dl\][^Ω^](#tf5-4){ref-type="table-fn"}   *r*           --0.015                                  --0.253[\*](#tf5-1){ref-type="table-fn"}   0.589[\*\*](#tf5-2){ref-type="table-fn"}

  *p*                                               0.894         0.018                                    0.001                                      

  Na \[mEq/l\]                                      *r*           0.04                                     0.021                                      0.13

  *p*                                               0.712         0.845                                    0.229                                      

  K \[mEq/l\]                                       *r*           --0.032                                  --0.08                                     0.099

  *p*                                               0.77          0.46                                     0.363                                      

  Ca \[mg/dl\]                                      *r*           0.031                                    0.122                                      --0.167

  *p*                                               0.774         0.259                                    0.121                                      

  P \[mg/dl\]                                       *r*           --0.078                                  --0.034                                    0.321[\*\*](#tf5-2){ref-type="table-fn"}

  *p*                                               0.47          0.752                                    0.002                                      

  Mg \[mg/dl\]                                      *r*           0.12                                     0.169                                      0.041

  *p*                                               0.267         0.118                                    0.707                                      

  Fe \[μg/dl\]                                      *r*           0.248[\*](#tf5-1){ref-type="table-fn"}   0.103                                      --0.207

  *p*                                               0.021         0.341                                    0.054                                      

  IMA \[ΔABSU\]                                     *r*           0.096                                    --0.211                                    0.488[\*\*](#tf5-2){ref-type="table-fn"}

  *p*                                               0.377         0.05                                     0.001                                      

  Albumin \[g/dl\]                                  *r*           0.015                                    0.162                                      --0.404[\*\*](#tf5-2){ref-type="table-fn"}

  *p*                                               0.893         0.134                                    0.001                                      

  IMA/ALB\                                          *r*           0.087                                    --0.213[\*](#tf5-1){ref-type="table-fn"}   0.503[\*\*](#tf5-2){ref-type="table-fn"}
  \[AU\]                                                                                                                                              

  *p*                                               0.421         0.048                                    0.001                                      

  CAT \[kU/l\]                                      *r*           0.08                                     0.280[\*\*](#tf5-2){ref-type="table-fn"}   --0.714[\*\*](#tf5-2){ref-type="table-fn"}

  *p*                                               0.461         0.009                                    0.001                                      

  MPO \[U/l\]                                       *r*           0.005                                    0.09                                       --0.152

  *p*                                               0.967         0.405                                    0.159                                      

  FOX \[U/l\]                                       *r*           --0.055                                  --0.011                                    0.394[\*\*](#tf5-2){ref-type="table-fn"}

  *p*                                               0.612         0.92                                     0.001                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Correlation is significant at the 0.05 level (2-tailed).

Correlation is significant at the 0.01 level (2-tailed).

Pearson correlation test

Spearman correlation analysis.

Discussion {#sec5}
==========

An elevation was detected in CRP, IMA, IMA/Alb, Cu, CAT and FOX levels in the patient group and a decrease was detected in albumin, Se and Zn levels. Increased oxidative stress is one of the main theories proposed for the etiopathogenesis of psoriasis. Consistent with this, in this study, serum oxidative stress biomarker levels were higher in the patient group compared to the control group.

Ataş *et al.* have revealed that the elevation in serum IMA and the decrease in serum albumin were closely related with oxidative stress and the increase in oxidative stress could be an important sign in pathogenesis and prognosis \[[@cit0028]\]. Özdemir *et al.* have detected a significant inverse correlation between IMA and serum albumin levels \[[@cit0029]\]. Consistent with these, in this study, serum IMA and IMA/ALB ratio was found to be high and albumin levels were lower in patients with psoriasis compared to the control group (*p* \< 0.001) ([Table 2](#t0002){ref-type="table"}). There was also a significant negative correlation between IMA and albumin levels in the patient group (*p* \< 0.001) ([Table 4](#t0004){ref-type="table"}). However, no correlation was found between IMA, IMA/Alb levels and severity of psoriasis. Elevated IMA levels support the assumption of increased oxidative stress in psoriasis.

Psoriasis is an inflammatory and proliferative disease of the skin \[[@cit0002]\]. C-reactive protein (CRP) is an acute phase protein released from the liver as response to IL-6 and a sensitive inflammation marker \[[@cit0007]\]. Recent studies have reported an association between elevated CRP levels and prognosis of psoriasis \[[@cit0007], [@cit0008], [@cit0030]\]. CRP levels were found to be statistically significantly higher in the patient group compared to the healthy group also in this study (*p* \< 0.001). However, we found a slight correlation between CRP and the severity of psoriasis (Table 4). Increased levels of CRP support the background of inflammation in psoriasis.

Selenium is an important trace element which shows anti-proliferative and immune-modulatory effects. This active compound plays a role in protective redox reactions against oxidative damage, mainly due to being the cofactor of glutathione peroxidase \[[@cit0006], [@cit0031]\]. Selenium deficiency is reported to be one of the risk factors which could lead to susceptibility to inflammatory skin diseases \[[@cit0031]--[@cit0033]\]. An ample amount of studies are available showing low serum Se concentration in psoriasis patients \[[@cit0006], [@cit0034], [@cit0035]\]. Kadry *et al.* have found that plasma Se levels were lower, osteopontin levels were extremely higher in the patient group compared to the control group and proposed that over-expression of osteopontin and low Se levels could be associated with the pathogenesis of psoriasis \[[@cit0036]\]. In the study of Seneczko, serum Se levels were shown to be significantly low beside erythrocytes in psoriasis patients as compared to controls \[[@cit0037]\]. We also detected that Se levels were lower in psoriasis patients as compared to controls (*p* = 0.006).

Some researchers reported that serum Zn levels were extremely low in psoriasis patients \[[@cit0038]--[@cit0041]\]. However Ala *et al.* \[[@cit0005]\] and Kreft *et al*. \[[@cit0042]\] did not find a statistically significant difference between psoriasis patients and healthy controls with regard to Zn levels. In our study, Zn levels were found to be statistically significantly lower in the patient group as compared to the control group (*p* \< 0.001) supporting the previous studies. In addition, our finding of the opposite relationship between Zn and CRP and IMA/ALB reveals that the level of Zn decreases in oxidative stress (Table 5). It has been reported that there is a negative relationship between surface area involvement and the serum Zn level in psoriasis patients. This may be due to a decrease in serum Zn level causing an increase in skin involvement or a result of excessive skin exfoliation causing zinc loss \[[@cit0043]\].

Copper is related with several metalloproteins and one fraction in serum (5%) binds to albumin loosely and another binds to globulin (ceruloplasmin) tightly \[[@cit0040]\]. As ceruloplasmin is an acute phase reactant and more than 90% of serum copper is transferred with ceruloplasmin, elevated Cu levels could only be an inflammation marker \[[@cit0040], [@cit0044]\]. Basavaraj *et al.* \[[@cit0018]\] evaluated Cu levels in psoriasis patients and found that serum Cu levels were higher in both mild and severe groups compared to the control group. Shahram Ala *et al.* found serum Cu levels higher in psoriasis patients compared to controls \[[@cit0005]\]. Similarly, in this study, Cu levels were higher in the patient group than in the control group (*p* \< 0.001). There was also a positive correlation between Cu and CRP (*p* \< 0.001, *r* = 0.589). Therefore, this increase in Cu seems to develop secondarily to elevation of ceruloplasmin, the acute phase protein. Nevertheless, our finding of an opposite relationship between Cu and albumin levels supports the argument that the level of albumin decreases with increased inflammation.

Excessive Fe levels were shown in various skin pathologies like psoriasis which contain inflammatory responses \[[@cit0045], [@cit0046]\]. Iron homeostasis was also shown to alter under oxidative stress conditions \[[@cit0045], [@cit0047]\]. Basavaraj *et al.* reported that serum Fe levels were lower both in mild and severe psoriasis patients compared to the control group \[[@cit0018]\]. In our study, although serum Fe levels were found to be higher in psoriasis patients compared to the control group, this difference was not statistically significant (*p* = 0.585).

Oxidative stress is among the main theories in psoriasis pathogenesis. Reactive oxygen species were reported to be responsible for angiogenesis in keratinocytes and uncontrolled transcription increase in psoriasis \[[@cit0048], [@cit0049]\]. CAT was found high in some studies \[[@cit0020], [@cit0023]\] and low in some others \[[@cit0021], [@cit0022]\]. In our study, a statistically significant increase was detected in CAT activity in the psoriasis group compared to the control group (*p* \< 0.001). However, there was a negative correlation between CAT and IMA/ALB (*p* \< 0.001, *r* = --0.489) ([Table 4](#t0004){ref-type="table"}). Taken together, the increase in CAT levels seems to develop as a defence mechanism against the increase in oxidative stress.

Myeloperoxidase is an enzyme which is used by neutrophils to form anti-microbial reactive oxygen species during phagocytosis. These oxidants kill the phagocytized bacteria, but when produced in excessive amounts, they also lead to tissue damage \[[@cit0050]\]. Yazıcı *et al.* found MPO levels higher than controls in psoriasis patients both in serum and the skin \[[@cit0012]\]. In our study, while MPO levels were found high, this difference was not statistically significant (*p* = 0.123).

Serum ceruloplasmin levels are generally measured indirectly as FOX activity. Although ceruloplasmin levels may increase in physiologic conditions like pregnancy, they usually increase in chronic inflammatory diseases and the fact that these pathologic conditions are related with ROS production is striking \[[@cit0051]\]. Ceruloplasmin represents a protein with specific domains capable of both facilitating cellular energy production and preventing oxygen radical formation \[[@cit0052]\]. Perhaps ceruloplasmin is increasing to prevent oxidant formation. Matoshvili *et al.* found serum ceruloplasmin levels higher in psoriasis patients compared to controls \[[@cit0023]\]. Similarly, we also found FOX activity levels higher in the patient group as compared to the control group (*p* \< 0.001). In addition, FOX activity showed a significant difference between disease severity groups as well (*p* = 0.004) ([Table 3](#t0003){ref-type="table"}, [Figure 1](#f0001){ref-type="fig"}). Ceruloplasmin is known to be an acute phase reactant. But perhaps the increase in psoriasis develops as a compensatory to oxidative stress.

![Ferroxidase (FOX) levels according to disease severity groups](PDIA-37-94265-g001){#f0001}

We did not detect a significant difference between patient and control groups with regard to Na, K, Ca, P and Mg levels.

The present study has some limitations. If we could measure the studied parameters not only in serum but also in urine, involved skin and uninvolved skin; and also if we could directly measure the oxidative stress level (like total oxidant status), we could make more reliable comments on the role of these parameters in etiopathogenesis of psoriasis.

Conclusions {#sec6}
===========

The present study has indicated that there are alterations in serum trace element levels and an increase in inflammation and oxidative stress in psoriasis patients. Supplementation of Se and Zn, and anti-oxidant therapy could positively influence the clinical course of the disease. However more comprehensive studies are required to explain the role of these findings in etiopathogenesis of psoriasis.
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